141 related articles for article (PubMed ID: 581766)
21. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
[No Abstract] [Full Text] [Related]
22. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
[No Abstract] [Full Text] [Related]
23. The relationship of thyroxine turnover to other parameters of peripheral thyroid function in Graves' disease.
Clifton-Bligh P; Burke G
J Lab Clin Med; 1975 Jun; 85(6):922-33. PubMed ID: 48532
[TBL] [Abstract][Full Text] [Related]
24. Triiodothyronine toxicosis developing during antithyroid drug therapy for hyperthyroidism.
Hollander CS; Shenkman L; Mitsuma T; Asper SP
Johns Hopkins Med J; 1972 Aug; 131(2):184-8. PubMed ID: 5068365
[No Abstract] [Full Text] [Related]
25. [Clinical significance of elevated serum triiodothyronine to thyroxine ratios in patients with Graves' disease treated with antithyroid drugs].
Takamatsu J
Nihon Naibunpi Gakkai Zasshi; 1983 Mar; 59(3):295-303. PubMed ID: 6190686
[No Abstract] [Full Text] [Related]
26. Iodinating activity of thyroid tissue in toxic diffuse goiter.
Nagataki S; Uchimura H; Ikeda H; Kuzuya N; Masuyama Y
J Clin Invest; 1977 Apr; 59(4):723-9. PubMed ID: 576614
[TBL] [Abstract][Full Text] [Related]
27. Thyrotoxicosis in pregnancy.
Emerson CH
Curr Ther Endocrinol Metab; 1994; 5():275-7. PubMed ID: 7704731
[No Abstract] [Full Text] [Related]
28. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the triiodothyronine suppression test by the twenty-minute and the twenty-four-hour thyroidal 131-I uptake in patients receiving thioamide drugs.
Nagataki S; Uchimura H; Matsuzaki F; Masuyama Y
J Clin Endocrinol Metab; 1974 Feb; 38(2):255-61. PubMed ID: 4812621
[No Abstract] [Full Text] [Related]
30. [Pharmacology and dosage of thyrostatic drugs].
Passath A; Leb G; Warnkross H
Acta Med Austriaca; 1987; 14(3-4):72-4. PubMed ID: 2447738
[TBL] [Abstract][Full Text] [Related]
31. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
32. [The inhibition test of thyroid function with triiodothyronine in hyperthyroid patients under medical therapy: comparison of the values obtained from measures of "early" uptake and in the organic phase].
Valentini F; Reschini E; Lodeserto A; Vivarelli S; Miedico D
Folia Endocrinol; 1968 Aug; 21(4):396-403. PubMed ID: 4185869
[No Abstract] [Full Text] [Related]
33. Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease.
Eliopoulos G; Daniels GH; Maloof F
Arch Intern Med; 1975 Sep; 135(9):1242-4. PubMed ID: 1174301
[TBL] [Abstract][Full Text] [Related]
34. [Metabolism of organic iodine studied after administration of labeled iodide].
Busnardo B; Casson F
Acta Isot (Padova); 1966 Dec; 6(2):129-47. PubMed ID: 4171572
[No Abstract] [Full Text] [Related]
35. Metabolic clearance rates of diiodotyrosine in man.
Singer PA; Nicoloff JT
J Clin Endocrinol Metab; 1972 Apr; 34(4):666-70. PubMed ID: 4111067
[No Abstract] [Full Text] [Related]
36. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil.
Sato H; Hattori M; Fujieda M; Sugihara S; Inomata H; Hoshi M; Miyamoto S
J Clin Endocrinol Metab; 2000 Nov; 85(11):4270-3. PubMed ID: 11095466
[TBL] [Abstract][Full Text] [Related]
38. [Follow up studies of the antithyroid drug therapy for hyperthyroidism with special emphasis on the clinical usefulness of TRH and T3-suppression tests during treatment (author's transl)].
Tamai H
Fukuoka Igaku Zasshi; 1978 Nov; 69(11):486-94. PubMed ID: 83955
[No Abstract] [Full Text] [Related]
39. [Suppression of the thyroid gland using l-triiodothyronine. Dependence on function, iodine uptake, size of the thyroid gland and age].
Heinze HG; Pabst HW; Sonntag A
Munch Med Wochenschr; 1968 Aug; 110(34):1875-84. PubMed ID: 5695744
[No Abstract] [Full Text] [Related]
40. Spiking expression of mu-crystallin mRNA during treatment with methimazole in patients with graves' hyperthyroidism.
Suzuki S; Takei M; Nishio S; Inaba H; Sato A; Yamazaki M; Shinomiya K; Hashizume K
Horm Metab Res; 2009 Jul; 41(7):548-53. PubMed ID: 19280551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
